Sublingual Glycine vs. Placebo on Attentional Difficulties and Hyperactivity in Prepuberal Children

NCT ID: NCT02655276

Last Updated: 2017-12-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-01-31
• Study Completion Date: 2016-05-31

Brief Summary

This study is designed to investigate effects on attentional performance and motoric activity of 100 mg microencapsulated glycine (Bidicin® from Biotiki®) compared to placebo after treatment with t.i.d. sublingual doses over 3 weeks each.

The primary objective of the study is to determine the effects on attentional performance and motoric activity of 100 mg microencapsulated Glycine (Bidicin® from Biotiki® ) compared to placebo after treatment with t.i.d. sublingual doses over 3 weeks each in children with low attentional performance and high motoric activity.

A number of 30 prepuberal boys and girls aged 6 - 14 years with low attentional performance and high motoric activity will be enrolled in this study. The prepuberal status will be determined by Tanner stages ≤ 3.

Detailed Description

Trial Design:

This study has a double-blind, randomized, two-period, cross-over design. The study population will be randomized equally to the sequence 1 (first 3 weeks microencapsulated Glycine, second 3 weeks placebo) or sequence 2 (first 3 weeks placebo, second 3 weeks microencapsulated Glycine). Study Agent/Placebo - Dosage and Route of Administration:

Study Agent/Placebo will first be dispensed at Visit 2 (day 0). Treatment assignments will be made in accordance with the randomization. At each visit (Visit 2 and Visit 3), subjects will receive two blisters for the 3 following weeks. Only qualified personnel may dispense study Agent/Placebo.

Investigational and reference treatment:

100 mg microencapsulated Glycine (Bidicin® from Biotiki® ) Placebo from Biotiki®

Study design:

This study will employ a double blind, randomized, placebo-controlled cross-over design. SKAMP raters and teachers will be blinded concerning the study Agent/Placebo.

Planned Study Time Schedule:

The study ends 10 weeks after enrollment of the last patient (total study end). Study duration for each patient is between 7 and 10 weeks (from inclusion) until the last visit (close-out visit).

Statistics:

Sample size calculation is based on the primary endpoint "mean of the SKAMP Combined score over all time points in the classroom setting". The study should have sufficient power to detect a difference between treatments if a moderate effect size (corresponding to Cohen's d=0.5) were present in parallel-group study in two independent patient groups. Assuming a correlation between measurements in the same patient of 0.6, this translates into an effect size of 0.56 in a cross-over trial comparing within patient measurements. With this effect size, 27 patients have to be included in the study, to achieve a power of 0.8 at a two-sided significance level of alpha=0.05. To account for a small number of drop-outs, 30 patients have to be randomized.

Data analysis: The trial will be analyzed according to the intention-to-treat principle. Efficacy measures will be evaluated by linear mixed models for repeated measurements.

Safety analyses will be performed for subjects who received at least one dose of microencapsulated Glycine/ placebo. Incidences of adverse events and of serious adverse events will be calculated.

Conditions

Motor Activity; Attention Deficit; Stress, Psychological

Keywords

microencapsulated glycine; attentional performance; motoric activity; hyperactivity

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

100 mg microencapsulated Glycine and then Placebo tablets

100 mg microencapsulated Glycine (Bidicin® from Biotiki® ) t.i.d. for the first three weeks and then Placebo t.i.d. from Biotiki® for the second three weeks.

Group Type: EXPERIMENTAL

microencapsulated Glycine

Intervention Type: OTHER

100 mg microencapsulated Glycine (Bidicin® from Biotiki® ) t.i.d.

Placebo tablets

Intervention Type: OTHER

Placebo t.i.d. from Biotiki® in a crossover-design.

Placebo tablets and then 100 mg microencapsulated Glycine

Placebo t.i.d. from Biotiki® for the first three weeks and then 100 mg microencapsulated Glycine (Bidicin® from Biotiki® ) t.i.d. for the second three weeks.

Group Type: EXPERIMENTAL

microencapsulated Glycine

Intervention Type: OTHER

100 mg microencapsulated Glycine (Bidicin® from Biotiki® ) t.i.d.

Placebo tablets

Intervention Type: OTHER

Placebo t.i.d. from Biotiki® in a crossover-design.

Interventions

microencapsulated Glycine

100 mg microencapsulated Glycine (Bidicin® from Biotiki® ) t.i.d.

Intervention Type: OTHER

Placebo tablets

Placebo t.i.d. from Biotiki® in a crossover-design.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Male and female subjects aged 6-14 years with Tanner stages 0 to 3 and attentional and/or hyperactivity problems.

2. Subjects with parents or a legal guardian, who will give written informed consent for the child to participate in the study. Additionally, assent to participate must be obtained from all children entering the study if the child is able to judge the nature, the meaning and the significance of the trial. Assent will be documented by the child´s signature on the consent form.

3. Health Status: Subjects must not have clinically significant diseases or clinically significant abnormal laboratory values as assessed during medical history and physical exam.

4. Subjects meeting minimum intelligence requirements: In the opinion of the investigator the subject must generally be functioning at age-appropriate levels academically, which should take into account any prior cognitive or academic testing (basic knowledge of reading, writing and calculating).

5. Subject has an ADHD-RS-IV total score ≥18.

6. Subjects already receiving behavioral therapies for HKS/ADHD or oppositional defiant disorder may continue to do sor during the course of the trial.

Exclusion Criteria

1. subjects with psychiatric disorders requiring current pharmacological treatment (e.g. major depression, psychosis)

2. Subjects with psychiatric or somatic conditions that may contraindicate the trial or confound efficacy or safety assessments.

3. Subjects with a history of drug abuse or current use of recreational drugs.

4. History of hypersensitivity to microencapsulated Glycine or placebo.

5. Subjects who are judged by the investigator as likely to be non-compliant with study procedures.

6. Use of any investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer.

7. History of malignancy of any organ system, treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin.

• Minimum Eligible Age: 6 Years
• Maximum Eligible Age: 14 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Biotiki

UNKNOWN

Sponsor Role: collaborator

Eberhard Schulz

OTHER

Sponsor Role: lead

Responsible Party

Eberhard Schulz

Prof. Dr.

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Eberhard Schulz, Prof. Dr.

Role: STUDY_DIRECTOR

University Hospital Freiburg

Locations

University Hospital

Freiburg im Breisgau, Baden-Wurttemberg, Germany

Countries

Germany

Other Identifiers

Classroom FR03

Identifier Type: -

Identifier Source: org_study_id